Biogen
DC · 15 filings, 2025
Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the treatment of neurological diseases. The company's primary products are dimethyl fumarate (Tecfidera), diroximel fumarate (Vumerity), interferon beta-1a (AVONEX), peginterferon beta-1a (Plegridy), and natalizumab (Tysabri), all for the treatment of multiple sclerosis (collectively 45% of 2024 revenues); nusinersen (Spinraza) for the treatment of spinal muscular atrophy (16.2% of 2024 revenues); omaveloxolone (Skyclarys) for the treatment of Friedreich's ataxia (4.0% of 2024 revenues); tofersen (Qalsody) for the treatment of ALS; and dimethyl fumarate (Fumaderm) for the treatment of severe plaque psoriasis. The company also produces 5 biosimilars (8.2% of 2024 revenues) and has collaborations with Genentech for several drugs (18.1% of 2024 revenues). via Wikipedia ↗
1Lobbies on
Its filings list: Health Issues · Medicare/Medicaid · Taxation/Internal Revenue Code · Medical/Disease Research/Clinical Labs · Pharmacy · Copyright/Patent/Trademark · Trade (domestic/foreign)
2Through these firms · 4
3Bills moving in its lanes
No bill names this company outright; these are recent bills in the sectors it lobbies.
- S 5236A bill to amend title XIX of the Social Security Act to ensure Medicaid coverage of mental health services…
- S 5225A bill to amend the Elementary and Secondary Education Act of 1965 to include certain curriculum expenses a…
- S 5227A bill to amend the Internal Revenue Code of 1986 to allow certain distributions from long-term qualified t…
- S 5232A bill to amend the Public Health Service Act to authorize rural residency planning and development grant p…
- S 5224A bill to improve training for airport drivers in the movement area at commercial service airports through…